Broiler and Turkey Feed Premix Integration Without Homogeneity Loss

Dinitolmide (3,5-dinitro-o-toluamide, C₈H₇N₃O₅, CAS 148-01-6) is received at integrated feed mills as a crystalline veterinary active pharmaceutical ingredient intended for geometric dilution into registered Type A medicated articles. In jurisdictions where 21 CFR 558.235 remains the reference registration, the compound is approved for prevention of coccidiosis in broiler chickens and turkey poults at final feed concentrations of 0.0125% (125 mg/kg) and 0.015% (150 mg/kg), respectively; these inclusion rates must be checked against national residue and withdrawal provisions because no single withdrawal period applies across all export markets. Medicated feed production is governed by 21 CFR 225.1 through 225.158 current good manufacturing practice requirements for medicated feed mills, while destination-specific compliance may also invoke Regulation (EU) 2019/4 for medicated feed intermediates and ISO 22000:2018 clause 8.5.2 for hazard analysis and control measure selection. The production sequence begins with sifting the neat API through a 500 µm sieve and pre-blending it with calcium carbonate or rice hull carrier at a ratio of 1:4 in a horizontal ribbon mixer operating at 60% to 70% fill volume and 20 rpm for 10 min; the pre-blend is then transferred to a twin-shaft paddle mixer for stepwise dilution with ground corn, soybean meal, and other ration components. Homogeneity is confirmed by collecting 10 thief probes across the mixer and assaying samples by HPLC-UV, with a release coefficient of variation not exceeding 5%. Segregation is controlled by maintaining post-mix drop heights below 1.5 m and by limiting crude fat in the carrier to 6% unless the API is first layered onto a mineral matrix. Terminal downstream articles include Type B and Type C medicated feeds, pelleted broiler starter/grower/finisher rations, crumbled turkey poult feeds, and 25% w/w dinitolmide Type A medicated articles for further dilution at integrated feed mills. The premix label must state the prohibition against use in laying birds producing eggs for human consumption unless explicitly permitted by the destination registration.

Where drinking-water delivery becomes unavoidable because feed intake collapses during clinical Eimeria acervulina or Eimeria tenella challenges, dinitolmide is prepared as a non-aqueous oral solution concentrate for veterinary use in non-food avian species or as a wet-milled oral suspension where aqueous dilution is required by the farm water system. The aqueous solubility of dinitolmide is below 0.1 mg/mL; therefore, a true single-phase solution for in-water medication is attainable only with aprotic co-solvent systems such as dimethyl sulfoxide, N-methyl-2-pyrrolidone, or glycofurol, and residual solvent exposure is controlled under VICH GL18(R) limits. Compliance with USP <795> governs the extent of nonsterile compounding, while preservative effectiveness in multidose containers is evaluated according to USP <51>; if the formulation is registered rather than extemporaneously compounded, the dossier must comply with Directive 2001/82/EC or the equivalent national veterinary medicinal product framework. A suspension concentrate for oral administration typically contains 5.0% w/v dinitolmide, 0.05% to 0.10% w/v polysorbate 80 as wetting agent, 0.20% to 0.30% w/v microcrystalline cellulose and carboxymethylcellulose sodium as suspending agent, and 0.18% w/v methylparaben plus 0.02% w/v propylparaben as preservative, with pH maintained between 4.5 and 6.5 to avoid alkaline hydrolysis of the nitrobenzamide ring. Processing uses a rotor-stator high-shear disperser at 5000 to 8000 rpm for 20 min, followed by passage through a colloid mill with a 0.05 mm gap and vacuum deaeration at -0.08 MPa; the final suspension is filled into amber polyethylene terephthalate bottles of 100 mL or 250 mL and administered through calibrated oral dosing pumps or proportional water medicators. Terminal products produced in this scenario are non-aqueous oral solution concentrates for veterinary prescription use, aqueous oral suspensions for flock water medication where registered, and oral drench suspensions for individual bird dosing.

Which Particle Size Threshold Governs Uniformity in 1:100 Diluted Premixes?

The particle size distribution of dinitolmide, rather than final concentration alone, determines whether a 1:100 dilution from a 25% Type A article to a 0.25% intermediate premix remains homogeneous during pneumatic conveying and subsequent feed-mill dilution. For this operation the API should be milled to a D50 of 10 µm to 35 µm and a D90 not exceeding 75 µm using a spiral jet mill with compressed air at 0.7 MPa; particle size is verified by laser diffraction according to ISO 13320:2020 or by analytical sieving according to USP <786>. The production process then shifts from simple mixing to dry granulation when the intermediate premix must be pressed into pellets or when dusting must be suppressed for worker safety. In a typical dry granulation line, dinitolmide is blended with lactose monohydrate or calcium sulfate dihydrate carrier, 2.0% to 5.0% w/w povidone K30 binder, and 0.5% to 1.0% w/w colloidal silicon dioxide glidant in a twin-screw continuous blender; the blend is compacted on a roller compactor at a hydraulic pressure of 8 MPa to 15 MPa, granulated through a 1.0 mm screen, and classified to retain a granule fraction of 180 µm to 710 µm. Fines below 180 µm are limited to 10% to prevent segregation, and granule moisture must remain below 5.0% as determined by Karl Fischer titration. Regulatory compliance for this intermediate is maintained under FAMI-QS Code version 6 and ISO 22000:2018 clause 8.5.2; batch release includes assay, uniformity of mass, and moisture, with HPLC-UV reproducibility of ±2% relative standard deviation. Terminal articles produced by this route include dust-reduced granulated premixes for feed-mill dosing, sachets for top-dressing onto feed, and pelletized carrier granules loaded to 0.25% or 0.5% dinitolmide for subsequent dilution to final broiler or turkey rations.

In captive game bird and zoo avian medicine, oral solids are manufactured from dinitolmide API when individual animal dosing cannot be delivered through feed because of poor appetite or flock hierarchy effects. Tablet and capsule compounding must conform to USP <795> for nonsterile preparations and USP <905> for uniformity of dosage units, while dissolution specification is assessed with USP <711> apparatus II at 50 rpm in 900 mL of 0.1 N hydrochloric acid. A directly compressible tablet matrix for birds weighing 0.5 kg to 2.0 kg may contain 10 mg to 50 mg dinitolmide per tablet, with excipients consisting of 65% to 75% w/w lactose monohydrate, 15% to 25% w/w microcrystalline cellulose, 2.0% to 5.0% w/w croscarmellose sodium as disintegrant, and 0.5% to 1.0% w/w magnesium stearate as lubricant; the API content is adjusted by geometric dilution and confirmed by HPLC-UV before the final blend is compressed. Compression is performed on a rotary tablet press with a compression force of 8 kN to 20 kN, target tablet hardness of 30 N to 70 N, and friability below 1.0% per USP <1216>. For capsule filling, the same granulation or blend is filled into size 3 or size 4 hard gelatin capsules using a tamping-pin capsule filler with weight variation not exceeding 5%; capsules are sealed with a 1:1 gelatin-water band and stored in high-density polyethylene bottles with desiccant. Parenteral injection is not among the registered routes for dinitolmide because the therapeutic site is the intestinal mucosa, and no published safe parenteral exposure limit has been established; therefore, injectable dosage forms are not compounded from this API. Tablet and capsule production should not occur in facilities that also handle amine-based feed additives or reducing sugars unless segregated balance-room controls and clean-down verification by swab testing are in place. Terminal products are direct-compression tablets, hard gelatin capsules, and powder aliquots for veterinary prescription to zoological and racing-pigeon practitioners.

When a Feed Mill Lacks Liquid Blending Capability, Dry Powder Layering Remains the Preferred Route

Dry powder layering onto an inert carrier is selected when a feed mill cannot handle liquid binding systems or when the finished premix must be stored for more than 12 months in tropical humidity without solvent migration. For dinitolmide, the solution route imposes logistical and safety constraints because the API is practically insoluble in water and requires solvent recovery if the finished formulation is a true solution; the dry powder route avoids that recovery step and preserves the crystalline stability of the nitrobenzamide structure. The dry powder process is performed by mixing dinitolmide with precipitated silica or calcium silicate at a ratio of 1:2 to 1:5, then layering the mixture onto a food-grade carrier such as corn cob granules or vermiculite in a pan coater or rotating drum at 20 rpm to 30 rpm for 15 min to 20 min. Final API content in the layered powder is controlled between 2.0% and 10.0% w/w, depending on the target top-dressing rate, and the powder is sieved through 250 µm to remove agglomerates before packaging. Standards applied to this operation are USP <1174> for powder flow and USP <786> for sieve analysis; cross-contamination limits are set at 10 mg/kg carryover for non-medicated feeds and are verified by rinse swab testing under an ISO 17025-accredited method. The operational boundary is strict: if ambient relative humidity exceeds 60%, the carrier must be pre-dried to below 5% moisture before layering to prevent API migration into hygroscopic dust fractions. Terminal products include dry top-dress powders for poultry houses, stable premix powders for extruded poultry diets, and carrier-layered granules for zoo diets in which wet mixing would soften the ration pellets. The powder is not a pharmaceutical dosage form and must not substitute for registered medicated feed in jurisdictions that require premix registration.

Before dinitolmide is released for any powder, granule, or premix application, the API powder is characterized because particle size, moisture, and residual solvent profile control blend uniformity in short-mix-time feed mills. The powder is tested by laser diffraction according to ISO 13320:2020, with D50 typically 10 µm to 35 µm and D90 not exceeding 75 µm; loss on drying is controlled below 0.5% using USP <731>; and residual solvents are reported according to VICH GL18(R) limits. Storage conditions for the API powder are 25 °C and 60% RH in double polyethylene bags inside sealed fibre drums, with retest intervals established by accelerated stability data at 40 °C and 75% RH for 6 months. The powder should not be exposed to alkaline carriers above pH 8.0, strong reducing agents, or direct sunlight for more than 48 h, because these conditions destabilize the nitroarene chromophore. In downstream powder and premix applications the API is pre-sifted through 300 µm and blended stepwise into carriers; the resulting products include 25% Type A medicated articles, 2.0% to 10.0% w/w intermediate premix powders, and ready-to-use top-dress powders for registered poultry operations. For complete feed the final dinitolmide level remains 125 mg/kg for broilers and 150 mg/kg for turkeys, requiring a 1:200 dilution from a 25% Type A article when the powder is introduced at the final mixing stage.